AVEO NASDAQ
AVEO Pharmaceuticals, Inc.
1W: +0.4%
1M: +0.7%
3M: +0.5%
1Y: +300.0%
3Y: +135.8%
5Y: -46.8%
$15.00
Last traded 2023-01-19 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$39M
+545.9% ▲
5Y CAGR: +72.9%
Gross Profit
$34M
+615.1% ▲
5Y CAGR: +68.5%
Operating Income
-$50M
-27.5% ▼
Net Income
-$61M
-71.9% ▼
EPS (Diluted)
$-1.78
-7.2% ▼
EBITDA
-$57M
-69.0% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $8M | $5M | $29M | $6M | $39M |
| YoY Growth | +201.4% | -28.6% | +432.4% | -79.1% | +545.9% |
| Cost of Revenue | $0 | $0 | $0 | $1M | $5M |
| Gross Profit | $8M | $5M | $29M | $5M | $34M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 79.3% | 87.8% |
| R&D Expenses | $25M | $21M | $18M | $23M | $26M |
| SG&A Expenses | $9M | $11M | $11M | $22M | $61M |
| Operating Expenses | $34M | $31M | $29M | $45M | $87M |
| Operating Income | -$29M | -$25M | -$374K | -$39M | -$50M |
| Operating Margin | -380.1% | -468.8% | -1.3% | -645.9% | -127.5% |
| Interest Expense | $2M | $2M | $2M | $2M | -$4M |
| Income Before Tax | -$65M | -$5M | $9M | -$36M | -$53M |
| Tax Expense | $101K | $0 | $0 | $0 | $8M |
| Net Income | -$65M | -$5M | $9M | -$36M | -$61M |
| Net Margin | -858.0% | -98.5% | 32.6% | -591.2% | -157.4% |
| EPS (Diluted) | $-6.14 | $-0.41 | $0.61 | $-1.66 | $-1.78 |
| EBITDA | -$63M | -$3M | $23M | -$34M | -$57M |
| Shares Outstanding | 11M | 13M | 15M | 21M | 34M |